RxDoctor Payments Data

Kiran Jayaram, MD

Clinical Cardiac Electrophysiology · San Antonio, TXNPI 1992777320

Payments from drug & device makers

$8,306in general payments, 2019–2025

Across 578 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Medtronic$883
  • Abbott$631
  • Johnson & Johnson$616
  • Acutus Medical, Inc.$453
  • Biosense Webster, Inc.$302
  • plus $860 from 12 others

What the payments were for

  • Consulting fees$150%
  • Travel & lodging$3494%
  • Food & beverage$7,94096%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,306 in reported general payments places this provider in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$566,123
Medicare patients
1,562
Services billed
8,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban488$544,844
XareltoRivaroxaban199$262,062
MultaqDronedarone Hcl31$48,428
Flecainide Acetate466$21,335
Dofetilide72$11,615
Propafenone Hcl ErPropafenone Hcl31$7,638
Metoprolol Succinate477$7,218
Dabigatran EtexilateDabigatran Etexilate Mesylate16$4,776
Amiodarone Hcl187$3,581
SotalolSotalol Hcl108$2,341
Diltiazem 24hr Er (Cd)Diltiazem Hcl78$2,231
ClopidogrelClopidogrel Bisulfate105$977
Digoxin42$945
Diltiazem 12hr ErDiltiazem Hcl13$729
Potassium Chloride40$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$234$544,844488 claims
Johnson & JohnsonXarelto$616$262,062199 claims
Sanofi-aventis U.S. LLCMultaq$47$48,42831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →